Appointments at Cytovance, MPI Research and UBC – People on the move
Cytovance Biologics has appointed Jeffrey Su as vice president (VP) of bioanalytical development. Su will head the bioanalytical development laboratory that Cytovance is adding to its production facility in Oklahoma City, Oklahoma, US.
Before joining Cytovance Su worked at Femta Pharmaceuticals and he has also help positions at Sanofi Pasteur, Dow Chemical and Roche during his 17 years in the industry.
Thomas Laughlin has joined MPI Research as executive VP of sales and marketing. Laughlin has more than 30 years experience in healthcare, most recently as CEO of SunHealth Solutions.
Earlier in his career Laughlin worked at Bayer, Pharmacia & Upjohn and Proctor & Gamble.
Akela Pharma, the parent company of contract services firm PharmaForm, has appointed Greg McKee as its CEO and Robert Rieder has taken the post of chairman.
McKee is a member of Akela’s board of directors and has more than 20 years experience in biotech management at companies including Nventa and Valentis.
Most recently Reider was CEO of Cardiome and he has also held positions at MDS Ventures Pacific and Synapse Technologies.
United BioSource Corporation (UBC) has appointed Bengt Winblad to its European scientific advisory board for central nervous system (CNS) clinical trials.
Winblad is a leading research into Alzheimer’s disease and will help UBC develop new approaches to ensure data quality in CNS trials.
He is currently professor of geriatric medicine and chief physician at the Karolinska University Hospital, Huddinge, and the Karolinska Institute in Stockholm, Sweden. Furthermore, Winblad is involved in an array of studies and reviews research centres in Europe and the US.
